Results 231 to 240 of about 1,263,658 (344)

Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real‐World: Results From the SCORE—Clinical ASCVD Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between semaglutide 2.4 mg and major adverse cardiovascular events (MACE) among adults with clinical atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity without diabetes in real‐world clinical practice.
Michael G. Nanna, Carlos Mena‐Hurtado, Victoria Divino, Zhenxiang Zhao, Yan Chen, Joanna Boland, Jinlin Song, Andrea Traina, Kerem Ozer, Filip K. Knop, Kim G. Smolderen   +10 more
wiley   +1 more source